DDInter1834 DDInter834
Topiramate is a anti-epileptic drug used to manage seizures and prevent migraines. It was initially approved by the FDA in 1996. In 2004, topiramate was approved for the prevention of migraine in adults.[A188309,L10544,L43478] Since 2012, the extended-release formulation has been approved in combination with [phentermine] for chronic weight management therapy in adults. Characteristics that distinguish topiramate from other antiepileptic drugs are a monosaccharide chemical structure containing a sulfamate, and 40% of its mass accounted for by oxygen. Interestingly, topiramate was discovered by chance when attempts were made to formulate a novel antidiabetic drug.
Glycopyrronium, also known as NVA237 or glycopyrrolate, is a racemic mixture of two enantiomers. They are both quaternary ammonium compounds and long acting muscarinic antagonists. It is one of the most commonly prescribed anticholinergic medications.[A233535,A233540] Early research into glycopyrronium use was for its indication as an adjunct therapy in the treatment of peptic ulcers.[A233570,L33090] Later research, taking advantage of the systemic distribution of muscarinic receptors through the body, found that glycopyrronium could also be used for reducing sweat gland, oral, airway, and gastric secretions; as well as reducing cardiac inhibitory reflexes; and reducing bronchoconstriction in COPD. Glycopyrronium is commonly prescribed as a first line treatment for a wide variety indications and is considered to have a wider therapeutic window than [tiotropium]. Glycopyrronium was originally granted FDA approval on 11 August 1961.
Topiramate {u} (Compound) causes {v} (Side Effect) Abdominal distension
Abdominal distension {u} (Side Effect) is caused by {v} (Compound) Glycopyrronium
Topiramate {u} (Compound) causes {v} (Side Effect) Abdominal distension
Abdominal distension {u} (Side Effect) is caused by {v} (Compound) Mepenzolate
Mepenzolate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glycopyrronium
Topiramate {u} (Compound) causes {v} (Side Effect) Cardiac disorder
Cardiac disorder {u} (Side Effect) is caused by {v} (Compound) Oxybutynin
Oxybutynin {u} (Compound) resembles {v} (Compound) Glycopyrronium
Topiramate {u} (Compound) causes {v} (Side Effect) Gastroenteritis
Gastroenteritis {u} (Side Effect) is caused by {v} (Compound) Hydrochlorothiazide
Hydrochlorothiazide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Glycopyrronium
Topiramate {u} (Compound) causes {v} (Side Effect) Hyperglycaemia
Hyperglycaemia {u} (Side Effect) is caused by {v} (Compound) Acetaminophen
Acetaminophen {u} may cause a minor interaction that can limit clinical effects when taken with {v} Glycopyrronium
Topiramate {u} (Compound) binds {v} (Gene) SCN1A
SCN1A {u} (Gene) is bound by {v} (Compound) Hexylcaine
Hexylcaine {u} (Compound) resembles {v} (Compound) Glycopyrronium
Topiramate {u} (Compound) causes {v} (Side Effect) Abnormal behaviour
Abnormal behaviour {u} (Side Effect) is caused by {v} (Compound) Dextropropoxyphene
Dextropropoxyphene {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glycopyrronium
Topiramate {u} (Compound) binds {v} (Gene) SCN1A
SCN1A {u} (Gene) is bound by {v} (Compound) Orphenadrine
Orphenadrine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glycopyrronium
Topiramate {u} (Compound) downregulates {v} (Gene) DLD
DLD {u} (Gene) is downregulated by {v} (Compound) Mepenzolate
Mepenzolate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glycopyrronium
Topiramate {u} (Compound) upregulates {v} (Gene) UBQLN2
UBQLN2 {u} (Gene) is downregulated by {v} (Compound) Mepenzolate
Mepenzolate {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Glycopyrronium
Topiramate (Compound) causes Abdominal distension (Side Effect) and Abdominal distension (Side Effect) is caused by Glycopyrronium (Compound)
Topiramate (Compound) causes Abdominal distension (Side Effect) and Abdominal distension (Side Effect) is caused by Mepenzolate (Compound) and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Glycopyrronium
Topiramate (Compound) causes Cardiac disorder (Side Effect) and Cardiac disorder (Side Effect) is caused by Oxybutynin (Compound) and Oxybutynin (Compound) resembles Glycopyrronium (Compound)
Topiramate (Compound) causes Gastroenteritis (Side Effect) and Gastroenteritis (Side Effect) is caused by Hydrochlorothiazide (Compound) and Hydrochlorothiazide may cause a minor interaction that can limit clinical effects when taken with Glycopyrronium
Topiramate (Compound) causes Hyperglycaemia (Side Effect) and Hyperglycaemia (Side Effect) is caused by Acetaminophen (Compound) and Acetaminophen may cause a minor interaction that can limit clinical effects when taken with Glycopyrronium
Topiramate (Compound) binds SCN1A (Gene) and SCN1A (Gene) is bound by Hexylcaine (Compound) and Hexylcaine (Compound) resembles Glycopyrronium (Compound)
Topiramate (Compound) causes Abnormal behaviour (Side Effect) and Abnormal behaviour (Side Effect) is caused by Dextropropoxyphene (Compound) and Dextropropoxyphene may cause a moderate interaction that could exacerbate diseases when taken with Glycopyrronium
Topiramate (Compound) binds SCN1A (Gene) and SCN1A (Gene) is bound by Orphenadrine (Compound) and Orphenadrine may cause a moderate interaction that could exacerbate diseases when taken with Glycopyrronium
Topiramate (Compound) downregulates DLD (Gene) and DLD (Gene) is downregulated by Mepenzolate (Compound) and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Glycopyrronium
Topiramate (Compound) upregulates UBQLN2 (Gene) and UBQLN2 (Gene) is downregulated by Mepenzolate (Compound) and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Glycopyrronium